An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

Summary

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda. There is no expanded access program available for the investigational agents per this protocol.

Timeline

Start

2019-09-11

Primary completion

2021-12-20

Completion

2022-10-26

Publications

• Ntellas P, Park H, Culm K, Lee J, Youssoufian H, Mockbee C, Uhlik M, Benjamin L, Chau I. Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes. Curr Oncol. 2026 May 28;33(6):319. doi: 10.3390/curroncol33060319.

Drugs

Indications